Advances in Cancer Treatment: The Rise of Oncology Drugs
Oncology Drugs can then be selected that specifically target these aberrations, inhibiting the growth and spread of cancer cells. Examples include therapies targeting mutations in the EGFR, BRAF, ALK, and ROS1 genes. Therapies such as EGFR inhibitors have shown significant success treating lung cancers with EGFR mutations, achieving response rates over 70% in some studies. BRAF and MEK inhibitors have also had great success treating melanomas with BRAF mutations.
